CERA

Science and Research

SCD411: A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity between SCD411 and Eylea® in Subjects with Neovascular Age-related Macular Degeneration

Overview

  • Principal Investigator
Dr Thanh Nguyen